$280,000.00 in Sales Expected for Infinity Pharmaceuticals Inc. (NASDAQ:INFI) This Quarter

Equities analysts expect Infinity Pharmaceuticals Inc. (NASDAQ:INFI) to post sales of $280,000.00 for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Infinity Pharmaceuticals’ earnings, with estimates ranging from $200,000.00 to $390,000.00. Infinity Pharmaceuticals posted sales of $150,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 86.7%. The company is scheduled to report its next quarterly earnings report on Thursday, March 12th.

On average, analysts expect that Infinity Pharmaceuticals will report full-year sales of $2.34 million for the current financial year, with estimates ranging from $1.13 million to $3.00 million. For the next financial year, analysts expect that the business will post sales of $1.52 million, with estimates ranging from $800,000.00 to $2.23 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Infinity Pharmaceuticals.

Infinity Pharmaceuticals (NASDAQ:INFI) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.02). The company had revenue of $0.34 million for the quarter, compared to analysts’ expectations of $0.85 million. Infinity Pharmaceuticals had a negative return on equity of 125.37% and a negative net margin of 1,519.91%.

Separately, B. Riley started coverage on shares of Infinity Pharmaceuticals in a research note on Monday, November 18th. They set a “buy” rating and a $3.50 target price on the stock. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $2.83.

Shares of INFI traded up $0.06 during mid-day trading on Friday, reaching $1.51. The stock had a trading volume of 423,900 shares, compared to its average volume of 235,693. Infinity Pharmaceuticals has a 52-week low of $0.82 and a 52-week high of $1.95. The firm has a market cap of $66.72 million, a price-to-earnings ratio of -1.99 and a beta of 1.82. The business’s fifty day moving average is $1.15 and its 200 day moving average is $1.22. The company has a debt-to-equity ratio of 0.11, a current ratio of 6.22 and a quick ratio of 6.22.

A number of large investors have recently made changes to their positions in the stock. Jacobs Levy Equity Management Inc. increased its holdings in Infinity Pharmaceuticals by 5.0% in the 2nd quarter. Jacobs Levy Equity Management Inc. now owns 201,438 shares of the biotechnology company’s stock valued at $363,000 after purchasing an additional 9,511 shares in the last quarter. Parametric Portfolio Associates LLC acquired a new position in shares of Infinity Pharmaceuticals during the 2nd quarter worth about $76,000. Finally, Renaissance Technologies LLC increased its stake in shares of Infinity Pharmaceuticals by 12.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,002,006 shares of the biotechnology company’s stock valued at $1,804,000 after acquiring an additional 110,806 shares during the last quarter. Hedge funds and other institutional investors own 51.46% of the company’s stock.

Infinity Pharmaceuticals Company Profile

Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.

Featured Story: 52-Week High/Low Prices For Stock Selection

Get a free copy of the Zacks research report on Infinity Pharmaceuticals (INFI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.